SB 771 would prohibit pharmaceutical companies from engaging in direct-to-consumer advertising of prescription drugs in Oklahoma. The bill defines direct-to-consumer pharmaceutical advertising broadly to include promotional communications aimed at consumers through television, radio, print, digital platforms, social media, streaming services, billboards, email, and text messaging. It also defines pharmaceutical companies broadly to include entities involved in the research, development, production, or distribution of prescription drugs.
The bill states legislative findings that such advertising can mislead consumers, distort medical decision-making, increase drug costs, and pressure physicians to prescribe advertised products. It cites examples such as OxyContin, Vioxx, and Zyprexa to support the claim that consumer drug advertising can contribute to public health harms. The measure would make each prohibited advertisement a separate offense and create a felony penalty for violations, punishable by up to a $500,000 fine, up to five years in prison, or both.
SB 771 includes several exceptions. It would not apply to educational materials given directly by health care providers to patients, internal communications within health care organizations, communications required by law, public health campaigns that do not promote a specific product, clinical trial or research recruitment that complies with legal and ethical standards, insurance coverage information, or patient assistance program communications that do not directly promote a specific drug. The bill is set to take effect July 1, 2025, but also contains an emergency clause for immediate effectiveness upon passage and approval.
The bill’s impact on state law would be significant because it would create a new prohibition in Title 63 against a common form of pharmaceutical marketing and establish criminal penalties for violations. It would affect drug manufacturers, marketers, media outlets, and digital advertisers that target Oklahoma residents, while leaving room for certain health education, coverage, and research-related communications. Because the bill is introduced as a new criminal offense with broad advertising restrictions, it would likely require affected companies to sharply alter marketing practices in the state.
The available context shows no recorded votes or committee debate, so there is no documented public sentiment from hearings. Based on the bill text alone, the measure appears motivated by concerns about consumer protection, public health, and prescription drug costs. The main likely point of contention is the breadth of the ban and the felony penalty, especially for a law that would restrict commercial speech and could affect legitimate drug information, patient outreach, and media advertising. Supporters would likely emphasize reducing misleading drug promotion and protecting patients, while opponents would likely focus on free-speech, commerce, and access-to-information concerns.
SB 771 would add new provisions to Title 63 of the Oklahoma Statutes prohibiting direct-to-consumer prescription drug advertising by pharmaceutical companies and creating felony penalties for violations. It would affect pharmaceutical manufacturers and marketers, as well as media and digital platforms used for consumer drug promotion, while carving out exceptions for provider education, required disclosures, public health campaigns, clinical trial recruitment, insurance coverage information, and patient assistance communications.
No committee transcript or vote record is available, so there is no documented legislative sentiment in the provided context. The bill’s findings indicate a strongly protective posture toward public health and consumer decision-making, suggesting the sponsor views direct-to-consumer drug advertising as harmful. The absence of recorded debate means support or opposition from lawmakers is not shown, but the proposal itself signals a reform-minded, restrictive approach to pharmaceutical marketing.
The principal contention is likely whether Oklahoma should ban direct-to-consumer pharmaceutical advertising at all, especially given the bill’s broad reach across television, radio, print, digital, streaming, email, text, and social media. Another likely point of dispute is the severity of the enforcement mechanism: each ad would be a separate offense, and violations would be felonies punishable by substantial fines and prison time. Critics would likely argue the bill sweeps too broadly and may implicate commercial speech and access to drug information, while supporters would argue the restrictions are necessary to prevent misleading marketing, reduce drug costs, and protect the doctor-patient relationship.